2009 Press releases


Displaying 1 - 10 of 29



21 December 2009
Clavis Pharma ASA receives NOK 20 million Loan from Innovation Norway to Support the Phase III Programme of Elacytarabine in Acute Myeloid Leukaemia

Clavis Pharma ASA (OSE: CLAVIS) announced today that it has received an unsecured loan of NOK 20 million (USD 3.2 million) from Innovation Norway to support the Phase III clinical programme ..


7 December 2009
Positive Phase II clinical data for Clavis Pharma's Elacytarabine presented at ASH Annual Meeting

Clavis Pharma ASA (OSE: CLAVIS) announces that positive clinical data from its Phase II study with its lead cancer product candidate elacytarabine in patients with late-stage acute myeloid leukaemia (AML) ...


4 December 2009
Positive Phase II clinical data for Clavis Pharma’s elacytarabine to be presented at ASH Annual Meeting 2009

Clavis Pharma ASA (OSE: CLAVIS) announces that positive clinical data from its Phase II study with its lead cancer product candidate elacytarabine in patients with late-stage acute myeloid leukaemia (AML) will be presented ...


24 November 2009
Clavis Pharma and Clovis Oncology Sign $380 Million Partnership for the Development and Commercialisation of Anti-Cancer Agent CP-4126

CP-4126 is a novel, lipid-conjugated form of gemcitabine designed by Clavis Pharma to improve treatment outcomes in patients with pancreatic and other solid tumours. -  Clavis Pharma to receive up to $380 million in staged payments, including a $15 million signing fee, ...


24 November 2009
Invitation to Meeting and Conference Call for Clavis Pharma’s $380 Million Partnering Agreement

Clavis Pharma ASA (OSE: CLAVIS), the clinical stage oncology focused pharmaceutical company, announced today a $380 million agreement for the further development ...


30 October 2009
The European Commission grants Orphan Drug Designation for Intravenous CP-4126 for the Treatment of Pancreatic Cancer

Clavis Pharma ASA (OSE: CLAVIS); the clinical stage oncology focused pharmaceutical company, announces today that the European Commission has granted Orphan Drug Designation ..


22 October 2009
Third Quarter Report 2009

Clavis Pharma ASA (OSE: CLAVIS); the clinical stage oncology focused pharmaceutical company, announces today its results for the third quarter 2009. Following positive Phase II results for elacytarabine in acute myeloid leukaemia (AML) ...


19 October 2009
Invitation to presentation of Clavis Pharma's third quarter results 2009

Clavis Pharma ASA (OSE: CLAVIS) releases the company's third quarter 2009 results on Thursday 22 October 2009 at ...


14 September 2009
The European Medicines Agency recommends Orphan Drug Designation of Intravenous CP-4126 for the Treatment of Pancreatic Cancer

"We are pleased that EMEA has recommended our application for orphan drug designation for Intravenous CP-4126, and we are looking forward to receiving the final ...


14 September 2009
Clavis Pharma to present at the 9th Annual Biotech in Europe Investor Forum

Clavis Pharma ASA (OSE: CLAVIS) has been invited to present at the 9th Annual Biotech in Europe Investor Forum, Zürich, on Monday 14 September, 2009. ..